The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer


Erica Carballo, Sharon Wu, Courtney Penn, Kartik Angara, Premal Thaker, Matthew Oberley, Thomas Herzog, Kristen Starbuck


  • Pembrolizumab and lenvatinib in combination (pembro-lenv) has resulted in improved outcomes compared to standard chemotherapy for second-line treatment of endometrial cancer (EC)
  • Lenvatinib currently is only indicated for microsatellite stable (MSS) tumors as it is associated with significant toxicities and many microsatellite instability high (MSI-H) tumors respond to pembrolizumab alone.
Download Publication